- Home
- ITCI
as 07-26-2024 4:00pm EST
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 8.2B | IPO Year: | N/A |
| Target Price: | $94.83 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $45.50 - $84.89 | Next Earning Date: | 08-07-2024 |
| Revenue: | $513,930,000 | Revenue Growth: | 65.45% |
| Revenue Growth (this year): | 45.57% | Revenue Growth (next year): | 39.15% |
Stock Insider Trading Activity of Intra-Cellular Therapies Inc. (ITCI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RIGGS RORY B | ITCI | Director | Jun 23 '24 | Sell | $75.57 | 4,462 | $337,193.34 | 116,600 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $67.12 | 64 | $4,295.68 | 0 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $66.47 | 4,475 | $297,453.25 | 64 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $67.32 | 29 | $1,952.28 | 0 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $66.54 | 1,100 | $73,194.00 | 29 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $65.28 | 4,453 | $290,691.84 | 1,129 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $66.93 | 6,618 | $442,942.74 | 0 | SEC Form 4 |
| Hineline Lawrence J. | ITCI | SVP of Finance, CFO | Mar 7 '24 | Sell | $66.26 | 6,514 | $431,617.64 | 6,618 | SEC Form 4 |
| Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $66.95 | 4,496 | $301,007.20 | 29,700 | SEC Form 4 |
| Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $66.37 | 8,636 | $573,171.32 | 34,196 | SEC Form 4 |
| Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $66.86 | 1,313 | $87,787.18 | 29,700 | SEC Form 4 |
| Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $65.92 | 1,729 | $113,975.68 | 31,013 | SEC Form 4 |
| Neumann Mark | ITCI | EVP, Chief Commercial Officer | Mar 7 '24 | Sell | $65.11 | 4,303 | $280,168.33 | 32,742 | SEC Form 4 |
| Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $66.38 | 31,958 | $2,121,372.04 | 1,059,063 | SEC Form 4 |
| Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $66.93 | 8,754 | $585,905.22 | 1,050,309 | SEC Form 4 |
| Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $64.80 | 14,541 | $942,256.80 | 1,056,333 | SEC Form 4 |
| Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $65.90 | 4,128 | $272,035.20 | 1,052,205 | SEC Form 4 |
| Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $66.81 | 1,590 | $106,227.90 | 1,050,615 | SEC Form 4 |
| Mates Sharon | ITCI | Chairman, President & CEO | Mar 7 '24 | Sell | $67.33 | 306 | $20,602.98 | 1,050,309 | SEC Form 4 |
| Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $66.14 | 12,912 | $853,999.68 | 220 | SEC Form 4 |
| Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $66.81 | 220 | $14,698.20 | 0 | SEC Form 4 |
| Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $65.82 | 6,107 | $401,962.74 | 1,238 | SEC Form 4 |
| Halstead Michael | ITCI | EVP and General Counsel | Mar 7 '24 | Sell | $66.70 | 1,238 | $82,574.60 | 0 | SEC Form 4 |
| Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $66.34 | 3,728 | $247,315.52 | 18,892 | SEC Form 4 |
| Durgam Suresh K. | ITCI | EVP, Chief Medical Officer | Mar 7 '24 | Sell | $66.86 | 2,722 | $181,992.92 | 16,170 | SEC Form 4 |
Latest Intra-Cellular Therapies Inc. News
ITCI Breaking Stock News: Dive into ITCI Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
MT Newswires
4 days ago
Needham Adjusts Intra-Cellular Therapies Price Target to $100 From $94, Maintains Buy Rating
Simply Wall St.
5 days ago
Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long
Zacks
17 days ago
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
MT Newswires
17 days ago
RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating
Zacks
a month ago
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Investor's Business Daily
a month ago
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
MT Newswires
a month ago
Needham Adjusts Intra-Cellular Therapies Price Target to $94 From $90, Maintains Buy Rating
Compare ITCI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITCI Intra-Cellular Therapies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.